SANOFI VIETNAM SHAREHOLDING COMPANY (CÔNG TY CỔ PHẦN SANOFI VIỆT NAM), tax code 0312233458, is a major foreign-invested pharmaceutical manufacturer with a firm footprint in Vietnam's Saigon Hi-tech Park. Registered as a joint stock company since March 29, 2013, SANOFI VIETNAM operates from its main production facility at Lot I-8-2, Road D8, Long Thanh My Ward, Thu Duc City, Ho Chi Minh City, while maintaining offices in Hanoi, Long An, and central Ho Chi Minh City. Its business scope includes the manufacture of pharmaceuticals, cosmetics, cleaning products, and R&D in natural sciences.

Owned primarily by two foreign entities—SANOFI AVENTIS SINGAPORE PTE. LTD. (42.5%) and SANOFI-AVENTIS PARTICIPATIONS of France (42.06%)—the company represents a strategic extension of global pharmaceutical conglomerate Sanofi’s reach into Southeast Asia. The remainder of shares (15.44%) is held by other investors.

In 2023, the company posted USD 153.41 million in revenue, an increase of 29.52% year-over-year, reflecting strong sales performance in Vietnam’s growing health market. However, net profit decreased slightly by 2.54% to USD 32.9 million, suggesting margin compression possibly due to rising input costs or heavier R&D expenditures. Equity also dipped slightly by 2.86%, settling at USD 80.6 million, while total assets stood at USD 113.98 million, down 3.61% from 2022.

Despite the minor contraction in some financial indicators, SANOFI VIETNAM SHAREHOLDING COMPANY maintains a robust balance sheet with working capital of USD 46.82 million, offering strong liquidity and operational resilience. This places the company in a stable credit position for suppliers and partners analyzing Vietnam private financial data. It is led by General Director Ms. Tieu B. H., alongside Director Mr. Emin T., who oversees operations and compliance within Vietnam’s regulated pharmaceutical landscape.

From a risk management perspective, Sanofi’s performance in Vietnam appears stable and strategic, albeit with signs of capital plateauing in 2023. As a key player in research, manufacturing, and regional distribution, the firm’s operational transparency, capital backing, and revenue scale make it a benchmark entity for business verification in the country’s pharmaceutical industry.

 SANOFI VIETNAM SHAREHOLDING COMPANY is a leading pharmaceutical manufacturer in Vietnam with deep foreign backing and multi-site operations. While profit and asset figures showed a slight dip, overall sales growth and liquidity strength affirm its importance in both Vietnam’s health ecosystem and the regional portfolio of its French parent.